The company has not filed an annual or quarterly report since its FY2018 10-K, filed Mar 7, 2019. Its latest SEC filing is a 15-12B from May 3, 2019.
10-K for FY2018, filed Mar 7, 2019
The sections below describe the company as of the FY2018 annual report.
Develops investigational cancer therapies aimed at cancer growth, resistance, recurrence and spread, for people with solid tumors and other cancers.
10-K for FY2018, filed Mar 7, 2019
Pharmaceutical partners pay upfront fees, development milestones and research-cost reimbursements; Celgene's agreement also provides option payments and royalties on product sales.
10-K for FY2018, filed Mar 7, 2019We have not generated any revenue from product sales. Our revenue to date has been primarily derived from upfront payments and development…View ↗
The following table summarizes our revenue for the years ended December 31, 2018, 2017 and 2016, which is related to the recognition of…View ↗
The Company evaluated its existing contracts and only applied Topic 606 to those contracts that were not completed at January 1, 2018. As a…View ↗
$44.4M
10-K for FY2018, filed Mar 7, 2019
$44.4M ↗
Pharmaceutical companies pay OncoMed under research collaboration agreements; its collaborators included Celgene and Bayer, with GSK identified as a former collaborator.
10-K for FY2018, filed Mar 7, 2019
No. It lost $8.1M in FY2018.
10-K for FY2018, filed Mar 7, 2019
10-K for FY2018, filed Mar 7, 2019
−$10MView ↗
10-K for FY2018, filed Mar 7, 2019
−$8.1MView ↗
10-K for FY2018, filed Mar 7, 2019
−$45.5MView ↗
8-K, filed Apr 23, 2019
At the effective time of the Merger (the “Effective Time”), each share of common stock of OncoMed, par value $0.001 per share (the “OncoMed…View ↗
Grew. Revenue grew 12% in 4 years, from $39.6M in FY2014 to $44.4M in FY2018, about 3% a year.
Pipeline focus
The older report described a wider set of cancer-drug programs, including demcizumab, tarextumab, vantictumab and ipafricept; the latest centers on navicixizumab and etigilimab and says GITRL-Fc will not advance beyond its current trial.
10-K for FY2015, filed Mar 10, 2016 10-K for FY2018, filed Mar 7, 2019We have seven internally discovered product candidates in clinical development and have treated over 1000 patients across all of our…View ↗
Demcizumab (Anti-DLL4, OMP-21M18). Demcizumab is a first-in-class humanized monoclonal antibody that inhibits Delta-like Ligand 4, or DLL4…View ↗
Vantictumab (Anti-Fzd7, OMP-18R5). Vantictumab is a fully human monoclonal antibody, identified by screening against the Frizzled7…View ↗
OncoMed is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that address the fundamental biology driving…View ↗
Etigilimab (Anti-TIGIT, OMP-313M32). T-cell immunoreceptor with immunoglobulin and ITIM domains, or TIGIT, is an inhibitory receptor that…View ↗
We currently have two therapeutic candidates in active clinical development targeting key cancer pathways, including pathways regulating…View ↗
Collaboration roster
The older report described collaborations with GSK, Bayer and Celgene; the latest identifies Celgene and Bayer as current collaborators and GSK as a former collaborator.
10-K for FY2015, filed Mar 10, 2016 10-K for FY2018, filed Mar 7, 2019Collaborate with our partners, GSK, Bayer, and Celgene, to advance specific CSC and immuno-oncology programs forward in clinical…View ↗
We have not generated any revenue from product sales. Our revenue to date has been primarily derived from upfront payments and development…View ↗
Competes with AbbVie, ABL Bio, Genentech (Roche), Merck, Bristol-Myers Squibb, Arcus Biosciences, Amgen, Astellas, AstraZeneca, Bayer, Celgene, GSK, Johnson & Johnson, Lilly, Merck Serono, Novartis, Pfizer, Regeneron, Sanofi, and Teva
10-K for FY2018, filed Mar 7, 2019Established pharmaceutical and biotechnology companies that are known to be involved in oncology research and currently sell or are…View ↗
Loading...
